Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04158739
Title Flotetuzumab for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Children's Oncology Group

acute myeloid leukemia


Cytarabine + Flotetuzumab

Age Groups: adult | child
Covered Countries USA

No variant requirements are available.